Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$7.15

-1.4 (-16.37%)

19:46
09/20/17
09/20
19:46
09/20/17
19:46

Iovance Biotherapeutics 7.69M share Secondary priced at $6.50

The deal priced at $6.50, below today's closing price of $7.15, which was a decline of over 16% on the trading day. Iovance Biotherapeutics intends to use the net proceeds from this offering to fund its current and future clinical trials for its product candidates, including its ongoing Phase 2 clinical trials of LN-144, TIL for treatment of metastatic melanoma, and LN-145, TIL for the treatment of cervical and head and neck cancers, to fund activities related to commercial scale-up of the company's TIL product manufacturing operations; and for working capital and other general corporate purposes. Jefferies and Wells Fargo acted as joint book running managers for the offering.

  • 25

    Sep

  • 21

    Sep

IOVA Iovance Biotherapeutics
$7.15

-1.4 (-16.37%)

08/03/17
OPCO
08/03/17
INITIATION
Target $13
OPCO
Outperform
Iovance Biotherapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach initiated Iovance Biotherapeutics with an Outperform and a $13 price target saying its tumor infiltrating lymphocytes therapy has been clinically validated by several academic institutions and expects to see a stream of clinical readouts from three ongoing company-sponsored trials in the next 12-18 month. Breidenbach expects lovance's path to commercialization in solid tumors to be simplified due to to the trailblazing of personalized CAR-T therapies for blood cancers.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
09/01/17
WELS
09/01/17
NO CHANGE
WELS
Outperform
Iovance fast track designation 'particularly validating,' says Wells Fargo
Wells Fargo analyst Jim Birchenough views Iovance Biotherapeutics' fast track designation from the FDA for its tumor infiltrating lymphocyte product LN-144 as "particularly validating for a novel cell therapy." The designation establishes unmet need for patients and could support a "more reasonable" Phase 3 hurdle, Birchenough tells investors in a research note. He has an Outperform rating on Iovance.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $16
HCWC
Buy
Iovance expanding on multiple fronts, says H.C. Wainwright
Iovance Biotherapeutics released data at ESMO that it can generate highly active tumor infiltrating lymphocytes from lymphoma tumors, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note titled "Targeting Liquid Tumors and Automating the Supply Chain; Iovance Expanding on Multiple Fronts." The analyst says that while clinical efficacy of these expanded TILs remains unknown, he sees "significant safety profile differentiation" when compared to CAR-Ts. He notes that Iovance is also building new partnerships to make the supply chain run more efficiently. Pantginis keeps a Buy rating on the shares with a $16 price target.

TODAY'S FREE FLY STORIES

PERY

Perry Ellis

$27.92

0.31 (1.12%)

05:29
06/18/18
06/18
05:29
06/18/18
05:29
Hot Stocks
Perry Ellis enters into $437M 'going private' deal led by George Feldenkreis »

Perry Ellis announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

05:27
06/18/18
06/18
05:27
06/18/18
05:27
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

05:27
06/18/18
06/18
05:27
06/18/18
05:27
Hot Stocks
Cytokinetics announces data from reldesemtiv Phase 2 clinical study »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBSV

ObsEva

$14.53

-0.72 (-4.72%)

05:26
06/18/18
06/18
05:26
06/18/18
05:26
Conference/Events
ObsEva to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

MDT

Medtronic

$86.78

0.2 (0.23%)

, ISRG

Intuitive Surgical

$490.49

-5.17 (-1.04%)

05:25
06/18/18
06/18
05:25
06/18/18
05:25
Recommendations
Medtronic, Intuitive Surgical analyst commentary  »

Piper continues to…

MDT

Medtronic

$86.78

0.2 (0.23%)

ISRG

Intuitive Surgical

$490.49

-5.17 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

JD

JD.com

$43.63

-0.12 (-0.27%)

, GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

05:22
06/18/18
06/18
05:22
06/18/18
05:22
Hot Stocks
Google to invest $550M cash in JD.com as part of strategic partnership »

JD.com (JD) and Google…

JD

JD.com

$43.63

-0.12 (-0.27%)

GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Oct

NVS

Novartis

$75.80

-0.19 (-0.25%)

05:20
06/18/18
06/18
05:20
06/18/18
05:20
Hot Stocks
Alcon AcrySof IQ PanOptix trifocal IOL shows superior performance in trial »

Alcon, the global leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYCEY

Rolls-Royce

$0.00

(0.00%)

05:20
06/18/18
06/18
05:20
06/18/18
05:20
Upgrade
Rolls-Royce rating change  »

Rolls-Royce upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASBFY

Associated British Foods

$0.00

(0.00%)

05:18
06/18/18
06/18
05:18
06/18/18
05:18
Upgrade
Associated British Foods rating change  »

Associated British Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACGL

Arch Capital

$80.43

-0.69 (-0.85%)

05:16
06/18/18
06/18
05:16
06/18/18
05:16
Initiation
Arch Capital initiated  »

Arch Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNR

RenaissanceRe

$123.82

-0.33 (-0.27%)

05:15
06/18/18
06/18
05:15
06/18/18
05:15
Initiation
RenaissanceRe initiated  »

RenaissanceRe initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRB

W. R. Berkley

$75.33

0.06 (0.08%)

05:14
06/18/18
06/18
05:14
06/18/18
05:14
Initiation
W. R. Berkley initiated  »

W. R. Berkley initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RE

Everest Re

$226.37

0.38 (0.17%)

05:13
06/18/18
06/18
05:13
06/18/18
05:13
Initiation
Everest Re initiated  »

Everest Re initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$65.82

-0.17 (-0.26%)

05:13
06/18/18
06/18
05:13
06/18/18
05:13
Initiation
Arthur J. Gallagher initiated  »

Arthur J. Gallagher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$18.28

-0.52 (-2.77%)

05:12
06/18/18
06/18
05:12
06/18/18
05:12
Initiation
Kiniksa initiated  »

Kiniksa initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

GSKY

GreenSky

$24.27

-0.18 (-0.74%)

05:11
06/18/18
06/18
05:11
06/18/18
05:11
Initiation
GreenSky initiated  »

GreenSky initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, XPO

XPO Logistics

$113.89

2.225 (1.99%)

05:11
06/18/18
06/18
05:11
06/18/18
05:11
Hot Stocks
Nestle, XPO Logistics co-creating 638,000-square-foot distribution center in UK »

Nestle (NSRGY) and XPO…

NSRGY

Nestle

$0.00

(0.00%)

XPO

XPO Logistics

$113.89

2.225 (1.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPN

Global Payments

$117.51

-0.24 (-0.20%)

05:09
06/18/18
06/18
05:09
06/18/18
05:09
Downgrade
Global Payments rating change  »

Global Payments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVOP

EVO Payments

$22.98

0.95 (4.31%)

05:05
06/18/18
06/18
05:05
06/18/18
05:05
Initiation
EVO Payments initiated  »

EVO Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$130.91

0.81 (0.62%)

05:04
06/18/18
06/18
05:04
06/18/18
05:04
Downgrade
Chubb rating change  »

Chubb downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$60.17

-0.585 (-0.96%)

05:02
06/18/18
06/18
05:02
06/18/18
05:02
Downgrade
Leidos rating change  »

Leidos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDFN

Redfin

$24.00

-0.64 (-2.60%)

, ZG

Zillow

$65.24

0.45 (0.69%)

05:00
06/18/18
06/18
05:00
06/18/18
05:00
Downgrade
Redfin, Zillow rating change  »

Redfin downgraded to Sell…

RDFN

Redfin

$24.00

-0.64 (-2.60%)

ZG

Zillow

$65.24

0.45 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZG

Zillow

$65.24

0.45 (0.69%)

04:58
06/18/18
06/18
04:58
06/18/18
04:58
Downgrade
Zillow rating change  »

Zillow downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRG

Evergy

$52.75

0.8 (1.54%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Evergy management to meet with Wolfe Research »

Wolfe Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

MDT

Medtronic

$86.78

0.2 (0.23%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Medtronic management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.